24/7 Patient Assistance: 760-405-8205
24/7 Patient Assistance: 760-405-8205
Conditions Treated Laryngeal Cancer Lung Cancer
Hospitals & Clinics
specialties & services
Dr. Scott Antonia graduated the medical school from University of Connecticut School of Medicine and completed both his internship and fellowship program at Yale New Haven Hospital. He is specialized and board certified in medical oncology and has been practicing medicine for more than 20 years. Dr. Antonia is affiliated with Moffitt Cancer Center and during his career, he has also published several writings of medical interest in collaboration with other doctors.
University Of Connecticut School Of Medicine Graduated in 1989
Medical School
Yale New Haven Hospital Completed in 1990
Internship
Yale New Haven Hospital Completed in 1991
Residency
Yale University School Of Med Completed in 1994
Fellowship
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA Lancet Oncol. 2016 Mar;17(3):299-308.
See more >>
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.
Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ BMC Cancer. 2016 Mar;16(1):176.
See more >>
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD J Clin Oncol. 2016 Jun
See more >>
